Unlawful Stem Cell Products Continue to Harm People as FDA Deadline Looms
Congressional oversight could boost efforts to ensure safe, effective regenerative therapies
More than two years after the Food and Drug Administration updated its regulatory framework for regenerative medicine, hundreds of businesses continue to sell unapproved stem cell products and other drugs derived from human blood and tissue.
The framework clarified how the agency would oversee the growing market for these products, and it encouraged the development of new therapies while also aiming to restrain the proliferation of unproven—and often dangerous—stem cell treatments.
Businesses were given three years to come into compliance, a period that ends this November. But the FDA has signaled that many clinics and providers have yet to heed approval requirements for their products.
Read the remainder of this article at The Hill.
Spotlight on Mental Health
MORE FROM PEW
Explore Pew’s new and improved
Fiscal 50 interactive
Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:
- Maps, trends, and customizable charts
- 50-state rankings
- Analysis of what it all means
- Shareable graphics and downloadable data
- Proven fiscal policy strategies
Welcome to the new Fiscal 50
Key changes include:
- State pages that help you keep track of trends in your home state and provide national and regional context.
- Interactive indicator pages with highly customizable and shareable data visualizations.
- A Budget Threads feature that offers Pew’s read on the latest state fiscal news.